Lupin signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada

Global pharma major Lupin Limited (Lupin), today announced that it has signed a licence and supply agreement with Spektus Pharma (Spektus), a specialty pharmaceutical company to commercialize the novel antidepressant DeslaFlex™ in Canada.

DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab™ oral drug-delivery platform.

This strategic partnership combines Lupin's strong commercial footprint in Canada and Spektus's capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex™ and establish a robust platform for future launches. The collaboration further strengthens Lupin's CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.

"This milestone reinforces our long-term commitment to advancing Lupin's CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalized, patient-focused care," said Claus Jepsen, President, Global Specialty, Lupin.

Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said, "This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin's global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex™ for patients across this important market."

Shares of Lupin Limited was last trading in BSE at Rs. 2220.50 as compared to the previous close of Rs. 2199.20. The total number of shares traded during the day was 25988 in over 3148 trades.

The stock hit an intraday high of Rs. 2239.30 and intraday low of 2193.00. The net turnover during the day was Rs. 57726171.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals License SupplyAgreement Spektus